CCM
ATNM icon

Consonance Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Consonance Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-88,428
Closed -$690K – 39
2020
Q4 		$690K Sell
88,428
-704,742
-89% -$7.66M 0.06% 36
2020
Q3 		$7.69M Sell
793,170
-440,163
-36% -$4.85M 0.94% 21
2020
Q2 		$13M Buy
+1,233,333
New +$9.34M 0.78% 25

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Consonance Capital Management's ATNM Position: Q1 2021 in Review

Consonance Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2021, closing a stake of 88,428 shares — an estimated $690K sold.

Consonance Capital Management first reported a position in ATNM in Q2 2020 and held it in 3 quarters. The position peaked at $13M in Q2 2020. 40 funds tracked by Wall St. Rank hold ATNM as of Q1 2021.

  • Consonance Capital Management reported no remaining Actinium Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 88,428 Actinium Pharmaceuticals shares in Q1 2021, an estimated $690K.
  • Consonance Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Consonance Capital Management's Actinium Pharmaceuticals position peaked at $13M in Q2 2020.
  • 40 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.